Full Text View
Tabular View
No Study Results Posted
Related Studies
Lumbar Spinal Fibrosis and TNF Alpha Inhibition
This study is currently recruiting participants.
Study NCT00385086   Information provided by Assistance Publique - Hôpitaux de Paris
First Received: October 4, 2006   Last Updated: April 30, 2007   History of Changes

October 4, 2006
April 30, 2007
February 2007
 
Sciatica pain
Same as current
Complete list of historical versions of study NCT00385086 on ClinicalTrials.gov Archive Site
Functional assessments
Same as current
 
Lumbar Spinal Fibrosis and TNF Alpha Inhibition
Efficacy of TNF-Alpha Inhibition in Sciatica With Post-Operative Lumbar Spinal Fibrosis

TNF-alpha is the main cytokine implicated in the formation of lumbar spinal fibrosis. Inhibiting TNF-alpha could significantly decrease spinal fibrosis after lumbar discectomy.

OBJECT:

Failed back surgery syndrome is still a challenging therapeutic problem. Clinical studies have demonstrated a significant association between lumbar spinal fibrosis after lumbar discectomy and the recurrence of radicular pain in 25% of cases. Forceful epidural infiltrations, radiotherapy, therapy with D-penicillamine or surgical procedures have had unfavourable results in terms of pain and cost. Magnetic resonance imaging reveals lumbar spinal fibrosis by a hyposignal in the T1 sequence and a hypersignal in T2 sequence around the spinal tissue. Tumor necrosis factor a (TNF-a) is the main cytokine implicated in the formation of tissue fibrosis. In animal models of fibrosis, TNF-a inhibition has been shown to prevent and treat tissue fibrosis.

HYPOTHESIS:

Inhibiting TNF-a could significantly decrease sciatica pain because of lumbar spinal fibrosis after lumbar discectomy by decreasing spinal fibrosis.

METHODS:

We propose a 2-year pilot prospective, randomized, double-blind, controlled study of TNF-a inhibitor (infliximab) in patients with sciatica as a result of postoperative lumbar spinal fibrosis. The infliximab group will receive one intravenous injection of 3 mg/kg infliximab. The control group will receive one physiological serum injection. Patients will be evaluated at day 0, 10, 30, 90, and 180. The main evaluation criterion will be sciatica pain as measured on a visual analog scale, with the objective of a 50% decrease in pain at day 10. This objective leads to a size of 20 patients per group. The other evaluation criteria will be clinical, functional, social, and professional. Patients will be recruited from the rehabilitation unit at Cochin teaching hospital.

Phase III
Interventional
Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Post Operative Sciatica by Lumbar Spinal Fibrosis
Drug: TNF blocker
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
40
November 2008
 

Inclusion Criteria:

  • age over 18 years old
  • sciatica post discectomy
  • Pain with VAS > 40 mm and impossibility to have his usual activity
  • Surgical discectomy (less than 2 years and more than 6 months)
  • Painless of more than one month and less than one year after the discectomy
  • MRI with gadolinium injection of less than 6 months and done more than 6 months after the discectomy
  • Presence of spinal fibrosis on MRI (hyposignal in T1 enhanced by gadolinium and hypersignal in T2)
  • failure of epidural injection treatment
  • absence of tuberculosis
  • contraception for woman
  • informed consent

Exclusion Criteria:

  • Chronic psychiatric pathologies not treated
  • Presence of conflict between nerve root and herniated disc or disc fragments or spinal stenosis
  • severe cognitives troubles
  • severe cardiac failure (class III or IV)
  • Tuberculosis (active or latent), severe infections
  • Cancers
  • Allergy reactions to the drug studied
  • Difficulties to understand french
  • Patients enrolled in another clinical trial in the past three months
  • pregnancy, breastfeeding or no contraception
Both
18 Years and older
No
Contact: Francois Rannou, MD, PhD +33158412535 francois.rannou@cch.aphp.fr
Contact: Raphael Serreau, MD +33158411180 raphael.serreau@cch.aphp.fr
France
 
NCT00385086
 
P050312
Assistance Publique - Hôpitaux de Paris
 
Principal Investigator: Francois Rannou, MD, PhD AP-HP
Assistance Publique - Hôpitaux de Paris
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP